Tositumomab
From Proteopedia
(Difference between revisions)
Line 19: | Line 19: | ||
! Tositumomab | ! Tositumomab | ||
! 167000 | ! 167000 | ||
- | ! | + | ! 205800 |
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
Line 37: | Line 37: | ||
! 64.8 | ! 64.8 | ||
! 68 | ! 68 | ||
- | ! | + | ! 206 |
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
Line 49: | Line 49: | ||
! .078 | ! .078 | ||
! .017 | ! .017 | ||
- | ! | + | ! .009 |
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
Line 58: | Line 58: | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
- | ! Dosage | + | ! Dosage |
! Tositumomab | ! Tositumomab | ||
- | ! 500 (4th Infusion) | + | ! 500 mg (4th Infusion) |
- | ! | + | ! 325 mg/m<sup>2</sup> (4th Infusion) |
! Ibritumomab | ! Ibritumomab | ||
|- | |- |
Revision as of 07:16, 6 December 2010
Pharmacokinetics
Anti-CD20 Monoclonal Antibody Pharmacokinetics [1] | ||||
---|---|---|---|---|
Parameter | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
Tmax (hr) | Tositumomab | 7.6 | Rituximab | Ibritumomab |
Cmax (ng/ml) | Tositumomab | 167000 | 205800 | Ibritumomab |
Bioavailability (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
Protein Binding (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
T1/2 (hr) | 64.8 | 68 | 206 | Ibritumomab |
AUC (ng/ml/hr) | Tositumomab | 32939000 | Rituximab | Ibritumomab |
Clearance (L/h) | .078 | .017 | .009 | Ibritumomab |
IC50 (nM) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
Dosage | Tositumomab | 500 mg (4th Infusion) | 325 mg/m2 (4th Infusion) | Ibritumomab |
Metabolism | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |